Estrella Immunopharma, INC 8-K filings

Estrella Immunopharma, Inc. announced the results of its Combined 2025/2026 Annual Meeting of Stockholders, where the appointment of Macias Gini & OConnell LLP as its independent registered public accounting firm was ratified.

Estrella Immunopharma, Inc. received a Nasdaq notice for failing to hold its annual shareholder meeting, but plans to submit a compliance plan and convene a meeting by April 2026.

Estrella Immunopharma completed an $8.0 million registered direct offering and concurrent private placement to fund general corporate purposes and working capital.

Estrella Immunopharma's EB103 CD19 CAR-T therapy has advanced to Phase II of its STARLIGHT-1 trial following positive safety and efficacy data, including a 100% complete response rate in the high-dose Phase I cohort.

Estrella Immunopharma announced the successful completion of the second dose cohort in its STARLIGHT-1 Phase I/II clinical trial of EB103, reporting a 100% complete response rate.

Estrella Immunopharma, Inc. announced it has regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements.

Estrella Immunopharma, Inc. announced the immediate appointment of Jia Dengyao to its Board of Directors, effective September 22, 2025.

Estrella Immunopharma, Inc. received a Nasdaq notice for failing to meet the minimum Market Value of Listed Securities requirement.

Estrella Immunopharma, a clinical-stage biopharmaceutical company, announced the activation of a second clinical site for its Phase I/II STARLIGHT-1 trial evaluating EB103 for relapsed or refractory B-cell non-Hodgkins lymphoma.

Estrella Immunopharma, a clinical-stage biopharmaceutical company, announced a private placement equity financing of approximately $3.35 million to fund its lead cancer immunotherapy program, EB103, for B-cell non-Hodgkins lymphoma.

Estrella Immunopharma announced the initiation of dosing in the second cohort of its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-redirected ARTEMIS T-cell therapy for advanced B-Cell Non-Hodgkins Lymphomas, following positive safety data and a complete response observed in the first cohort.

Estrella Immunopharma received a notification from Nasdaq regarding non-compliance with the minimum bid price rule, potentially leading to delisting of its common stock and warrants.

Estrella Immunopharma reports positive initial results from its STARLIGHT-1 Phase I/II clinical trial for EB103 T-cell therapy and gains approval to proceed with a higher dose cohort.

Estrella Immunopharma announced that D. Boral Capital initiated coverage with a Buy rating and a 12-month price target of $16.00, citing the potential of its ARTEMIS T-cell therapy platform.

Estrella Immunopharma has successfully regained compliance with Nasdaq's minimum stockholders' equity and minimum bid price requirements, resolving previous non-compliance issues.

Estrella Immunopharma has amended its stock purchase agreement with White Lion Capital, extending the term and introducing a rapid purchase mechanism for faster share sales.

Estrella Immunopharma has changed its fiscal year end from June 30 to December 31 to align with the calendar year, necessitating a transition period from July 1, 2024, to December 31, 2024.

Estrella Immunopharma has received notices from Nasdaq regarding non-compliance with minimum stockholders' equity and minimum bid price requirements, placing its listing at risk.

Estrella Immunopharma has amended its previous 8-K filing to include details of a consulting agreement with a firm owned by its Chairperson, Hong Zhang, including compensation and equity grants.

Estrella Immunopharma has formalized an employment agreement with its CEO, Dr. Cheng Liu, effective November 1, 2024, outlining his compensation and terms of employment.

Estrella Immunopharma has appointed Hong Zhang as Chairperson of the Board, increasing the board size from five to six directors, following the dosing of the first patient in its Phase I/II clinical trial for EB103.

Estrella Immunopharma has announced the dosing of the first patient in its Phase I/II clinical trial for EB103, an autologous T-cell therapy targeting relapsed/refractory B-cell Non-Hodgkins Lymphomas.

Estrella Immunopharma, Inc. merged with its wholly-owned subsidiary, Estrella Biopharma, Inc., to streamline its corporate structure and financial reporting.

Estrella Immunopharma has amended its service agreement with Eureka Therapeutics, clarifying termination clauses related to their EB103 clinical trial.

Estrella Immunopharma is developing next-generation CD19-targeted ARTEMIS T-cell therapies for cancer and autoimmune diseases, leveraging a 'Mark and Kill' strategy for solid tumors.

Estrella Immunopharma plans to repurchase up to $1 million of its common stock over the next 12 months using existing cash reserves.

Estrella Biopharma has engaged Eureka Therapeutics for clinical trial services for its EB103 cancer therapy, with a total contract value of $33 million.

Estrella Immunopharma has dismissed Marcum LLP as its independent auditor and appointed Macias Gini & O'Connell, effective January 30, 2024.

Estrella Immunopharma's board has authorized a share repurchase program of up to $1 million, signaling confidence in the company's value and long-term potential.